Advertisement

Fish Oil Based Lipid Emulsions for the Treatment of Intestinal Failure Associated Liver Disease: Nothing Fishy About it!

  • Rishi Bolia
  • Anshu SrivastavaEmail author
Editorial Commentary
  • 14 Downloads

Intestinal failure (IF) is a condition in which the gut is unable to provide adequate nutrient and fluid requirements for the maintenance of metabolic functions and growth in children. Long-term parenteral nutrition (PN) is the backbone of management, however it is complicated by intestinal failure associated liver disease (IFALD) in ~20% children [1]. IFALD is defined as hepatic dysfunction as a consequence of the medical and surgical management strategies for IF. Serum bilirubin is a marker of IFALD, value of >1.2 mg/dl is considered a “red flag” and > 5.8 mg/dl is suggestive of marked liver injury [1]. IFALD varies in severity from biochemical cholestasis to end stage liver disease requiring liver ± intestinal transplantation. Risk factors for IFALD include prematurity, lack of enteral nutrition, sepsis, longer duration and constituents of PN [1].

In this issue, Miura et al. report a premature infant with short bowel syndrome on PN who developed IFALD, which was successfully treated...

Notes

Compliance with Ethical Standards

Conflict of Interest

None.

References

  1. 1.
    Lacaille F, Gupte G, Colomb V, et al. ESPGHAN Working Group of Intestinal Failure and Intestinal Transplantation. Intestinal failure-associated liver disease: a position paper of the ESPGHAN Working Group of Intestinal Failure and Intestinal Transplantation. J Pediatr Gastroenterol Nutr. 2015;60:272.Google Scholar
  2. 2.
    Miura W, Nagano N, Kato R, et al. Intestinal failure-associated liver disease and eicosapentaenoic acid/arachidonic acid ratio. Indian J Pediatr 2019 Feb 13.  https://doi.org/10.1007/s12098-019-02895-7. [Epub ahead of print].
  3. 3.
    Hojsak I, Colomb V, Braegger C, et al. ESPGHAN Committee on Nutrition. ESPGHAN Committee on Nutrition Position Paper. Intravenous lipid emulsions and risk of hepatotoxicity in infants and children: a systematic review and meta-analysis. J Pediatr Gastroenterol Nutr. 2016;62:776.Google Scholar
  4. 4.
    Park HW, Lee NM, Kim JH, Kim KS, Kim SN. Parenteral fish oil-containing lipid emulsions may reverse parenteral nutrition-associated cholestasis in neonates: a systematic review and meta-analysis. J Nutr. 2015;145:277.CrossRefGoogle Scholar
  5. 5.
    Lam HS, Tam YH, Poon TC, et al. A double-blind randomised controlled trial of fish oil-based versus soy-based lipid preparations in the treatment of infants with parenteral nutrition-associated cholestasis. Neonatology. 2014;105:290.CrossRefGoogle Scholar
  6. 6.
    Wang C, Venick RS, Shew SB, et al. Long-term outcomes in children with intestinal failure-associated liver disease treated with 6 months of intravenous fish oil followed by resumption of intravenous soybean oil. J Parenter Enter Nutr. 2018 Nov 8.  https://doi.org/10.1002/jpen.1463 [Epub ahead of print].
  7. 7.
    Norsa L, Nicastro E, Di Giorgio A, Lacaille F, D'Antiga L. Prevention and treatment of intestinal failure-associated liver disease in children. Nutrients. 2018;10:664.CrossRefGoogle Scholar
  8. 8.
    Belza C, Thompson R, Somers GR, et al. Persistence of hepatic fibrosis in pediatric intestinal failure patients treated with intravenous fish oil lipid emulsion. J Pediatr Surg. 2017;52:795.CrossRefGoogle Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2019

Authors and Affiliations

  1. 1.Division of Pediatric Gastroenterology, Department of GastroenterologyPGIMERChandigarhIndia
  2. 2.Department of Pediatric GastroenterologySGPGIMSLucknowIndia

Personalised recommendations